I dare to disagree with your instinct that "ts unlikely that all those in the pipeline will obtain full regulatory approval. Just my instincts here." WHY? It is a case by case basis for a specific disease treatment, just happened to be the same company and the same methodology used. It rather shows to me that this method has much more - some other "competitors" already working on some disease treatments than just one. It is something completely new in medical science coming to fruition. Once one is approved it will be easier to overcome fears of the new by the FDA and other authorities. This is just my view and the reasoning behind.
Ann: ODAC Votes in Favor of Remestemcel-L for GvHD, page-129
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.57 |
Change
-0.210(11.8%) |
Mkt cap ! $1.792B | |||
| Open | High | Low | Value | Volume |
| $1.72 | $1.74 | $1.52 | $15.63M | 9.716M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 5127 | $1.57 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.57 | 39613 | 3 |
View Market Depth
| Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
| MSB (ASX) Chart |